Japan health ministry approves Merck’s Keytruda QLEX for subcutaneous use across Keytruda indications
M
MRK• Japan approves subcutaneous Keytruda QLEX across indications
Japan’s health ministry cleared Merck’s subcutaneous Keytruda QLEX for all Keytruda indications approved in Japan.
The product, to be marketed as Keyject, can be administered in 1 minute every 3 weeks or 2 minutes every 6 weeks.
Approval relied on Phase 3 MK-3475A-D77 data showing comparable exposure and similar response rates versus IV Keytruda in metastatic NSCLC.
